Literature DB >> 21359002

Symptomatic cystic degeneration of a clinically silent corticotroph tumor of the pituitary gland.

Michael T Walsh1, William T Couldwell.   

Abstract

Clinically silent corticotroph tumors of the pituitary gland are those tumors that stain for adrenocorticotropic hormone (ACTH) but do not manifest with clinical or laboratory features of Cushing disease. These tumors have been described as exhibiting more aggressive behavior than other nonfunctional pituitary tumors. We present an unusual case of a clinically silent corticotropic adenoma of the pituitary gland that underwent cystic degeneration following recurrence after transsphenoidal surgery and radiation therapy. The patient underwent left frontotemporal craniotomy with resection of the suprasellar mass and decompression of the left optic nerve. Postoperative magnetic resonance imaging demonstrated no further optic chiasm or nerve compression. Patients with clinically silent ACTH-secreting tumors should be monitored for aggressive tumor behavior and may require closer follow-up than those patients harboring other nonfunctional tumors.

Entities:  

Keywords:  Cortisol; Cushing disease; adrenocorticotropic hormone; corticotroph cells; cystic degeneration; nonfunctional pituitary adenoma

Year:  2010        PMID: 21359002      PMCID: PMC3023327          DOI: 10.1055/s-0030-1253579

Source DB:  PubMed          Journal:  Skull Base        ISSN: 1531-5010


  11 in total

1.  Silent mixed corticotroph and somatotroph macroadenomas presenting with pituitary apoplexy.

Authors:  T Abe; M Taniyama; B Xu; H Ozawa; N Kawamura; M Shimazu; K Sasaki; H Izumiyama; M Kushima; J Kuwazawa; T Sano; K Matsumoto
Journal:  Acta Neuropathol       Date:  2001-11       Impact factor: 17.088

2.  Pituitary Cushing's disease arising from a previously non-functional corticotrophic chromophobe adenoma.

Authors:  N J Vaughan; C M Laroche; I Goodman; M J Davies; J S Jenkins
Journal:  Clin Endocrinol (Oxf)       Date:  1985-02       Impact factor: 3.478

3.  A spectrum of behaviour in silent corticotroph pituitary adenomas.

Authors:  S E Baldeweg; J R Pollock; M Powell; J Ahlquist
Journal:  Br J Neurosurg       Date:  2005-02       Impact factor: 1.596

4.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

5.  Metamorphosis of a non-functioning pituitary adenoma to Cushing's disease.

Authors:  E U Tan; M S Ho; C R Rajasoorya
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

6.  Cushing's disease arising from a clinically nonfunctioning pituitary adenoma.

Authors:  Luiz Roberto Salgado; Márcio Carlos Machado; Arthur Cukiert; Bernardo Liberman; Cristina Takami Kanamura; Venancio Avancini Ferreira Alves
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

7.  A novel type of pituitary adenoma: morphological features and clinical correlations.

Authors:  E Horvath; K Kovacs; H S Smyth; D W Killinger; B W Scheithauer; R Randall; E R Laws; W Singer
Journal:  J Clin Endocrinol Metab       Date:  1988-06       Impact factor: 5.958

8.  Silent corticotroph adenomas: further clinical and pathological observations.

Authors:  John A Lopez; B k Kleinschmidt-Demasters Bk; Chun-I Sze; Whitney W Woodmansee; Kevin O Lillehei
Journal:  Hum Pathol       Date:  2004-09       Impact factor: 3.466

9.  Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.

Authors:  K J Bradley; J A H Wass; H E Turner
Journal:  Clin Endocrinol (Oxf)       Date:  2003-01       Impact factor: 3.478

10.  Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study.

Authors:  K Michael Webb; Jeffrey J Laurent; David O Okonkwo; M Beatriz Lopes; Mary Lee Vance; Edward R Laws
Journal:  Neurosurgery       Date:  2003-11       Impact factor: 4.654

View more
  7 in total

Review 1.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

2.  A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Authors:  Nazanin Hosseinkhan; Maryam Honardoost; Zahra Emami; Sara Cheraghi; Nahid Hashemi-Madani; Mohammad E Khamseh
Journal:  Endocrine       Date:  2022-06-16       Impact factor: 3.925

Review 3.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

4.  Heterogeneity analysis of the proteomes in clinically nonfunctional pituitary adenomas.

Authors:  Xianquan Zhan; Xiaowei Wang; Ying Long; Dominic M Desiderio
Journal:  BMC Med Genomics       Date:  2014-12-24       Impact factor: 3.063

Review 5.  Human Pituitary Adenoma Proteomics: New Progresses and Perspectives.

Authors:  Xianquan Zhan; Xiaowei Wang; Tingting Cheng
Journal:  Front Endocrinol (Lausanne)       Date:  2016-05-31       Impact factor: 5.555

Review 6.  Exploration of Molecular Network Variations in Different Subtypes of Human Non-functional Pituitary Adenomas.

Authors:  Xianquan Zhan; Ying Long
Journal:  Front Endocrinol (Lausanne)       Date:  2016-02-10       Impact factor: 5.555

7.  A Preoperative MRI-Based Radiomics-Clinicopathological Classifier to Predict the Recurrence of Pituitary Macroadenoma Within 5 Years.

Authors:  Yu Zhang; Yuqi Luo; Xin Kong; Tao Wan; Yunling Long; Jun Ma
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.